MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-30-2025
Merit Medical Systems Net Debt 2011-2026 | MMSI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Merit Medical Systems
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 363 M | 248 M | 139 M | 177 M | 300 M | 395 M | 328 M | 246 M | 305 M | 203 M | 217 M | 241 M | 228 M | 23.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 395 M | 23.8 M | 244 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical instruments industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
-45 M | - | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
17.1 B | $ 184.86 | 1.31 % | $ 53.2 B | USA |
 |
Baxter International
BAX
|
7.55 B | $ 21.74 | 1.85 % | $ 11.2 B | USA |
 |
Luminex Corporation
LMNX
|
-106 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-517 K | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
-12.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
781 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
66.8 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.58 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
-411 M | - | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-5.61 M | $ 11.29 | -8.21 % | $ 228 M | USA |
 |
ICU Medical
ICUI
|
972 M | $ 155.85 | 4.08 % | $ 3.84 B | USA |
 |
Alcon
ALC
|
2.46 B | $ 82.21 | -1.21 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
-104 M | $ 32.79 | 1.27 % | $ 1.57 B | USA |
 |
electroCore
ECOR
|
-9.7 M | $ 6.16 | -0.16 % | $ 34 K | USA |
 |
Harvard Bioscience
HBIO
|
27.8 M | $ 0.58 | -0.56 % | $ 24.6 M | USA |
 |
LeMaitre Vascular
LMAT
|
145 M | $ 92.55 | 0.75 % | $ 2.08 B | USA |
 |
AngioDynamics
ANGO
|
-48.3 M | $ 11.22 | 0.13 % | $ 458 M | USA |
 |
InfuSystem Holdings
INFU
|
33.3 M | $ 7.9 | - | $ 163 M | USA |
 |
The Cooper Companies
COO
|
2.38 B | $ 84.11 | 0.51 % | $ 16.7 B | USA |
 |
Haemonetics Corporation
HAE
|
623 M | $ 61.61 | 1.55 % | $ 3.1 B | USA |
 |
iRhythm Technologies
IRTC
|
-154 M | $ 150.56 | -5.24 % | $ 4.82 B | USA |
 |
Isoray
ISR
|
-58.9 M | - | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
-21.6 M | $ 119.69 | 2.21 % | $ 5.8 B | USA |
 |
Repro Med Systems
KRMD
|
-10.8 M | $ 4.72 | 0.64 % | $ 215 M | USA |
 |
OraSure Technologies
OSUR
|
-266 M | $ 2.76 | -2.47 % | $ 205 M | USA |
 |
Masimo Corporation
MASI
|
572 M | $ 175.38 | 0.03 % | $ 9.35 B | USA |
 |
Intuitive Surgical
ISRG
|
-3.2 B | $ 504.2 | 0.93 % | $ 180 B | USA |
 |
Microbot Medical
MBOT
|
-2.24 M | $ 2.07 | -3.95 % | $ 21.1 M |  Israel |
 |
Nephros
NEPH
|
-2.48 M | $ 4.14 | 6.43 % | $ 43 M | USA |
 |
NeuroMetrix
NURO
|
-1.49 M | - | 5.05 % | $ 9.02 M | USA |
 |
Milestone Scientific
MLSS
|
-3.09 M | $ 0.26 | -2.04 % | $ 20.7 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.36 B | $ 12.63 | 0.88 % | $ 2.57 B | USA |
 |
Envista Holdings Corporation
NVST
|
276 M | $ 29.16 | 1.53 % | $ 4.9 B | USA |
 |
Pro-Dex
PDEX
|
15 M | $ 39.55 | 1.41 % | $ 130 M | USA |
 |
Pulse Biosciences
PLSE
|
-73.2 M | $ 21.98 | -12.38 % | $ 1.48 B | USA |
 |
Predictive Oncology
POAI
|
1.4 M | - | - | $ 31.1 M | USA |
 |
Stereotaxis
STXS
|
-14.3 M | $ 2.08 | -0.24 % | $ 168 M | USA |
 |
Repligen Corporation
RGEN
|
-236 M | $ 136.76 | -0.34 % | $ 7.62 M | USA |
 |
ResMed
RMD
|
513 M | $ 258.04 | 0.68 % | $ 37.7 B | USA |
 |
BioLife Solutions
BLFS
|
-88.9 M | $ 23.17 | -0.26 % | $ 1.07 B | USA |
 |
STERIS plc
STE
|
1.78 B | $ 250.32 | -0.34 % | $ 24.7 B | USA |
 |
Retractable Technologies
RVP
|
-3 M | $ 0.67 | -3.48 % | $ 20.1 M | USA |
 |
STAAR Surgical Company
STAA
|
-105 M | $ 17.65 | -1.29 % | $ 867 M | USA |
 |
Teleflex Incorporated
TFX
|
1.37 B | $ 115.88 | 3.65 % | $ 5.43 B | USA |
 |
Utah Medical Products
UTMD
|
-60.6 M | $ 67.96 | 2.09 % | $ 247 M | USA |
 |
West Pharmaceutical Services
WST
|
-566 M | $ 241.54 | -0.94 % | $ 17.5 B | USA |